Skip to main content
Clinical Trials/NCT03897387
NCT03897387
Completed
N/A

A Post-market, Multi-center, Retrospective Study to Identify Clinical Outcomes and Complications Data From Patients Implanted With the Medacta Versafit Cup DM Prosthesis Who Are at Least Two Years Post Surgery

Medacta USA3 sites in 1 country316 target enrollmentMarch 1, 2017
ConditionsHip Arthritis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hip Arthritis
Sponsor
Medacta USA
Enrollment
316
Locations
3
Primary Endpoint
Limb length
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is a post-market, retrospective with one prospective visit, multi- center study, designed to assess the clinical outcomes, surgical details including Anterior or Posterior surgical approach, and collect all complication data of Medacta Versafit Cup DM used for primary or revision total hip arthroplasty at minimum two year post- operatively.

Registry
clinicaltrials.gov
Start Date
March 1, 2017
End Date
March 30, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medacta USA
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects age 18 years and above at the time of consent
  • Able to understand the requirements of the study, provide a written informed consent and comply with the study protocol. Written informed consent must be obtained prior to any study procedure. 3 Patients must be willing to comply with the prospective visit schedule.
  • Patient underwent a primary or revision total hip replacement for any etiology (osteoarthritis, avascular necrosis, inflammatory arthritis, post- traumatic arthritis, hip fracture, failed prior procedures, etc.).
  • Patients must have received a Medacta Versafit Cup DM component
  • Patient must have adequate pre-operative and post-operative radiographs
  • Patients must be at minimum 2 year (24 months) post-treatment
  • The operation was performed by the investigator.

Exclusion Criteria

  • History of alcoholism
  • Currently on chemotherapy or radiation therapy
  • Habitual use of narcotic pain medications prior to surgery or after surgery for reasons other than hip pain
  • History of a metabolic disorder such as Gout affecting the skeletal system other than osteoarthritis or osteoporosis
  • History of chronic pain issues for reasons other than hip pain
  • Women that are pregnant
  • Patients who underwent Total Hip Arthroplasty (THA) using standard polyethylene

Outcomes

Primary Outcomes

Limb length

Time Frame: Minimum 2 years post surgery

Determined by radiographic analysis by measuring in millimeters

Implant position fixation and wear

Time Frame: Minimum 2 years post surgery

Determine by radiographic analysis by measuring Radio Lucent lines in millimeters

Dislocation rate of Medacta Versafit Cup DM

Time Frame: Minimum 2 years post surgery

Determine radiographic analysis of component position in millimeters

Patient Satisfaction and outcome score

Time Frame: Minimum 2 years post surgery

Determined by the Hip Disability and Osteoarthritis Outcome Score (HOOS) likert scale score

Secondary Outcomes

  • Patient questionnaire Harris Hip Score (HHS)(Minimum 2 years post surgery)
  • Surgical Approach(Minimum 2 years post surgery)
  • Gait analysis(Minimum 2 years post surgery)
  • Implant survivorship(Minimum 2 years post surgery)
  • Implant demographics(Minimum 2 years post surgery)
  • Complications(Minimum 2 years post surgery)
  • Patient questionnaire Forgotten Joint Score (FJS)(Minimum 2 years post surgery)
  • Patient questionnaire Likert Scale Score(Minimum 2 years post surgery)
  • Range of Motion(Minimum 2 years post surgery)

Study Sites (3)

Loading locations...

Similar Trials